CORVUS PHARMACEUTICALS INC (CRVS) Stock Price, Quote, News and Overview
NASDAQ:CRVS - Nasdaq - US2210151005 - Common Stock - Currency: USD
CRVS Quote, Performance and Key Statistics
3.61
+0.03 (+0.84%)
The current stock price of CRVS is 3.61 USD. In the past month the price increased by 11.42%. In the past year, price increased by 57.64%.
CRVS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.92 | 325.53B | ||
| AMGN | AMGEN INC | 13.12 | 146.46B | ||
| GILD | GILEAD SCIENCES INC | 13.24 | 127.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 112.77B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.41 | 64.17B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.11B | ||
| ARGX | ARGENX SE - ADR | 96.36 | 34.54B | ||
| ONC | BEIGENE LTD-ADR | 5.68 | 24.62B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.30B | ||
| NTRA | NATERA INC | N/A | 20.74B | ||
| BIIB | BIOGEN INC | 7.94 | 18.40B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.73B |
Related stock screener links
About CRVS
Company Profile
Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. The company is headquartered in Burlingame, California and currently employs 31 full-time employees. The company went IPO on 2016-03-23. The firm is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. ITK, an enzyme that functions in T cell signaling and differentiation, is expressed predominantly in T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.
Company Info
CORVUS PHARMACEUTICALS INC
863 Mitten Rd Ste 102
Burlingame CALIFORNIA 94010 US
CEO: Richard A. Miller
Employees: 31
Phone: 16509004520
CORVUS PHARMACEUTICALS INC / CRVS FAQ
What is the stock price of CORVUS PHARMACEUTICALS INC today?
The current stock price of CRVS is 3.61 USD. The price increased by 0.84% in the last trading session.
What is the ticker symbol for CORVUS PHARMACEUTICALS INC stock?
The exchange symbol of CORVUS PHARMACEUTICALS INC is CRVS and it is listed on the Nasdaq exchange.
On which exchange is CRVS stock listed?
CRVS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CORVUS PHARMACEUTICALS INC stock?
12 analysts have analysed CRVS and the average price target is 15.3 USD. This implies a price increase of 323.82% is expected in the next year compared to the current price of 3.61. Check the CORVUS PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CORVUS PHARMACEUTICALS INC worth?
CORVUS PHARMACEUTICALS INC (CRVS) has a market capitalization of 246.09M USD. This makes CRVS a Micro Cap stock.
How many employees does CORVUS PHARMACEUTICALS INC have?
CORVUS PHARMACEUTICALS INC (CRVS) currently has 31 employees.
What are the support and resistance levels for CORVUS PHARMACEUTICALS INC (CRVS) stock?
CORVUS PHARMACEUTICALS INC (CRVS) has a support level at 3.33 and a resistance level at 3.62. Check the full technical report for a detailed analysis of CRVS support and resistance levels.
Should I buy CORVUS PHARMACEUTICALS INC (CRVS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CRVS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CRVS, evaluating the profitability, health, valuation and growth aspects
- CORVUS PHARMACEUTICALS INC (CRVS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CORVUS PHARMACEUTICALS INC (CRVS) Sales and EPS estimates to see what analysts future expectations are.
- CORVUS PHARMACEUTICALS INC (CRVS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CORVUS PHARMACEUTICALS INC (CRVS) Insider and Institutional Ownership to learn about the owners and their transactions.
- CORVUS PHARMACEUTICALS INC (CRVS) Stock Chart to make your own analysis
- CORVUS PHARMACEUTICALS INC (CRVS) Latest news and press-releases to stay up to date.
Does CORVUS PHARMACEUTICALS INC (CRVS) stock pay dividends?
CRVS does not pay a dividend.
When does CORVUS PHARMACEUTICALS INC (CRVS) report earnings?
CORVUS PHARMACEUTICALS INC (CRVS) will report earnings on 2025-08-04.
What is the Price/Earnings (PE) ratio of CORVUS PHARMACEUTICALS INC (CRVS)?
CORVUS PHARMACEUTICALS INC (CRVS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.61).
What is the Short Interest ratio of CORVUS PHARMACEUTICALS INC (CRVS) stock?
The outstanding short interest for CORVUS PHARMACEUTICALS INC (CRVS) is 10.69% of its float. Check the ownership tab for more information on the CRVS short interest.
CRVS Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to CRVS. When comparing the yearly performance of all stocks, CRVS is one of the better performing stocks in the market, outperforming 87.98% of all stocks.
CRVS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CRVS. The financial health of CRVS is average, but there are quite some concerns on its profitability.
CRVS Financial Highlights
Over the last trailing twelve months CRVS reported a non-GAAP Earnings per Share(EPS) of -0.61. The EPS decreased by -17.31% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -90.4% | ||
| ROE | -191.27% | ||
| Debt/Equity | 0 |
CRVS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to CRVS. The Buy consensus is the average rating of analysts ratings from 12 analysts.